ATE386115T1 - Verwendung von proteinkinasen zur diagnose und behandlung der alzheimer krankheit - Google Patents

Verwendung von proteinkinasen zur diagnose und behandlung der alzheimer krankheit

Info

Publication number
ATE386115T1
ATE386115T1 AT98121177T AT98121177T ATE386115T1 AT E386115 T1 ATE386115 T1 AT E386115T1 AT 98121177 T AT98121177 T AT 98121177T AT 98121177 T AT98121177 T AT 98121177T AT E386115 T1 ATE386115 T1 AT E386115T1
Authority
AT
Austria
Prior art keywords
alzheimer
epitopes
tau protein
diagnosis
disease
Prior art date
Application number
AT98121177T
Other languages
English (en)
Inventor
Eva-Maria Mandelkow
Eckhard Mandelkow
Gerard Drewes
Jacek Biernat
Birgit Lichtenberg-Kraag
Barbara Steiner
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26129111&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE386115(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP91120974A external-priority patent/EP0544942A1/de
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of ATE386115T1 publication Critical patent/ATE386115T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/961—Chemistry: molecular biology and microbiology including a step of forming, releasing, or exposing the antigen or forming the hapten-immunogenic carrier complex or the antigen per se
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
AT98121177T 1991-12-06 1992-12-07 Verwendung von proteinkinasen zur diagnose und behandlung der alzheimer krankheit ATE386115T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP91120974A EP0544942A1 (de) 1991-12-06 1991-12-06 Neue Werkzeuge für die Diagnose und die Behandlung der Alzheimer-Krankheit
EP92119551 1992-11-16

Publications (1)

Publication Number Publication Date
ATE386115T1 true ATE386115T1 (de) 2008-03-15

Family

ID=26129111

Family Applications (4)

Application Number Title Priority Date Filing Date
AT98121177T ATE386115T1 (de) 1991-12-06 1992-12-07 Verwendung von proteinkinasen zur diagnose und behandlung der alzheimer krankheit
AT98121176T ATE438716T1 (de) 1991-12-06 1992-12-07 Verwendung von protein-kinasen zur diagnose und behandlung der alzheimer-krankheit
AT93901671T ATE185599T1 (de) 1991-12-06 1992-12-07 Werkzeuge für die diagnose und behandlung der alzheimerschen krankheit.
AT98121175T ATE398176T1 (de) 1991-12-06 1992-12-07 Phosphorylierungsepitope aus dem tau-protein zur diagnose und behandlung der alzheimer-krankheit

Family Applications After (3)

Application Number Title Priority Date Filing Date
AT98121176T ATE438716T1 (de) 1991-12-06 1992-12-07 Verwendung von protein-kinasen zur diagnose und behandlung der alzheimer-krankheit
AT93901671T ATE185599T1 (de) 1991-12-06 1992-12-07 Werkzeuge für die diagnose und behandlung der alzheimerschen krankheit.
AT98121175T ATE398176T1 (de) 1991-12-06 1992-12-07 Phosphorylierungsepitope aus dem tau-protein zur diagnose und behandlung der alzheimer-krankheit

Country Status (10)

Country Link
US (2) US6200768B1 (de)
EP (5) EP0911390B1 (de)
JP (4) JPH07507044A (de)
AT (4) ATE386115T1 (de)
AU (2) AU681071B2 (de)
CA (1) CA2125298A1 (de)
DE (4) DE69230148T2 (de)
DK (1) DK0618968T3 (de)
ES (2) ES2136654T3 (de)
WO (1) WO1993011231A1 (de)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010913A (en) * 1992-12-14 2000-01-04 N.V. Innogenetics S.A. Isolated human tau peptide
JPH06239899A (ja) * 1993-02-12 1994-08-30 Teijin Ltd ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法
GB2295395B (en) * 1993-08-12 1998-04-01 Inst Of Psychiatry Models of Alzheimer's disease
GB9316727D0 (en) * 1993-08-12 1993-09-29 Inst Of Psychiatry Models of alzheimers's disease
DE69434811T2 (de) * 1993-12-21 2007-03-01 Innogenetics N.V. Monoklonale antikörper gegen phf-tau, hybridomen die diese ausscheiden, antigenerkennung durch diesen antikörper und deren verwendungen
EP0772634B1 (de) * 1994-07-29 2003-03-12 Innogenetics N.V. Monoklonale antikörper gegen ein epitop einer gewissen unterklasse oder form von phosphoryliertem tau, hybridome die diese sezernieren,antigenerkennung durch diese antikörper und deren verwendung
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
GB9610829D0 (en) * 1996-05-23 1996-07-31 Medical Res Council Screening of agents for treatment of azlheimers disease
US7252950B1 (en) 1997-09-04 2007-08-07 The Regents Of The University Of California Assays for detecting modulators of cytoskeletal function
ES2263218T3 (es) * 1997-09-04 2006-12-01 The Board Of Trustees Of The Leland Stanford Junior University Ensayos para detectar moduladores de la funcion del citoesqueleto.
US6797478B1 (en) 1998-03-05 2004-09-28 University Of Cincinnati Method of detecting axonal damage, from associated disease states using tau monoclonal antibodies
TWI241298B (en) 1998-09-25 2005-10-11 Mitsubishi Chem Corp Pyrimidone derivatives
US20020002270A1 (en) 1999-06-16 2002-01-03 Raymond P. Zinkowski Purified antigen for alzheimer's disease, and methods of obtaining and using same
US7146209B2 (en) * 2000-05-08 2006-12-05 Brainsgate, Ltd. Stimulation for treating eye pathologies
US7640062B2 (en) 2000-05-08 2009-12-29 Brainsgate Ltd. Methods and systems for management of alzheimer's disease
US20030162230A1 (en) 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
KR100960256B1 (ko) 2001-02-27 2010-06-01 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 유사분열 촉진인자-활성화 단백질 키나제 인산화에 근거한 알쯔하이머병 진단
EP1925315A3 (de) * 2001-02-27 2009-11-18 Blanchette Rockefeller Neurosciences Institute Alzheimer-Diagnose auf Basis von mitogenaktivierter Proteinkinasephosphorylierung
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
GB0117326D0 (en) 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
WO2003037888A1 (en) 2001-09-21 2003-05-08 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
NZ531637A (en) 2001-09-21 2005-12-23 Mitsubishi Pharma Corp 3-substituted-4-pyrimidone derivatives as tau protein kinase 1 inhibitor
US7794965B2 (en) * 2002-03-13 2010-09-14 Signum Biosciences, Inc. Method of identifying modulators of PP2A methylase
CA2483635A1 (en) * 2002-04-25 2003-11-06 Alon Shalev Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head
US7684859B2 (en) * 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
JP2006515999A (ja) * 2002-11-14 2006-06-15 ブレインズゲート リミティド 刺激のための外科用ツール及び技法
US7683069B2 (en) 2002-12-16 2010-03-23 Mitsubishi Tanabe Pharma Corporation 3-substituted-4-pyrimidone derivatives
EP1576001A2 (de) * 2002-12-18 2005-09-21 Novartis AG Peptide, die spezifisch an endotheliale zellen binden
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
GB2398533B (en) * 2003-02-19 2005-11-16 Gillette Co Safety razors
TWI357408B (en) 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives
WO2005058374A1 (en) * 2003-12-15 2005-06-30 Tongji Medical Center Methods and compositions for modulating tau in vivo
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
WO2006021957A2 (en) * 2004-08-23 2006-03-02 Brainsgate Ltd. Concurrent bilateral spg modulation
US7790881B2 (en) 2004-09-23 2010-09-07 Wista Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC)
US8221804B2 (en) * 2005-02-03 2012-07-17 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
JP2009506302A (ja) * 2005-08-04 2009-02-12 イェシバ・ユニバーシティ Ａｂｌによるタウのリン酸化
US20090029873A1 (en) 2005-10-11 2009-01-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb)
CA2628703C (en) 2005-11-30 2019-10-29 Abbott Laboratories Anti-a.beta. globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
DK2013191T6 (en) 2006-03-29 2019-04-23 Wista Lab Ltd 3,7-Diamino-10H-phenothiazine salts and their use
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
CA2645946C (en) 2006-03-29 2014-04-01 Wista Laboratories Ltd. Inhibitors of protein aggregation
US20090210026A1 (en) * 2006-08-17 2009-08-20 Brainsgate Ltd. Spg stimulation for enhancing neurogenesis and brain metabolism
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20110086908A9 (en) * 2007-01-22 2011-04-14 Roger Nitsch Use of phosphatase inhibitors for the treatment of neurodegenerative diseases
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
WO2010014588A1 (en) 2008-07-28 2010-02-04 Blanchette Rockefeller Neurosciences Institute Stimulus-elicited genomic profile markers of alzheimer's disease
EP2328572B1 (de) 2008-07-28 2018-06-13 Blanchette Rockefeller Neurosciences, Institute Pkc-aktivierende verbindungen zur behandlung von neurodegenerativen erkrankungen
WO2010021755A2 (en) * 2008-08-20 2010-02-25 Oligomerix, Inc. Tau protease compositions and methods
US9464122B2 (en) * 2008-08-20 2016-10-11 Oligomerix, Inc. Methods and compositions comprising tau oligomers
FR2940972B1 (fr) * 2009-01-09 2015-07-31 Isp Investments Inc Nouveaux peptides anti-age et composition cosmetique et/ou pharmaceutique les contenant
CN102365021B (zh) * 2009-02-05 2015-07-15 伊缪诺金公司 新型苯并二氮杂*衍生物
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
EP2440234A4 (de) * 2009-06-10 2013-11-06 Univ New York Immunologische anzielung pathologischer tau-proteine
RU2518291C2 (ru) * 2009-07-30 2014-06-10 Пфайзер Вэксинс ЭлЭлСи Антигенные tau-пептиды и их применения
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
AU2010286501B2 (en) 2009-08-28 2015-06-11 The Board Of Regents Of The University Of Texas System Antibodies that bind Tau oligomers
JP5681719B2 (ja) * 2009-09-24 2015-03-11 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル タウ機能不全を伴う神経障害を処置するための新規な治療ターゲットとしてのｆｋｂｐ５２−タウ相互作用
US20110144029A1 (en) * 2009-09-30 2011-06-16 Board Of Regents, The University Of Texas System Model Systems and Materials for the Study and Treatment of Neurodegenerative Diseases
JP6058395B2 (ja) 2009-10-02 2017-01-11 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート アルツハイマー病の診断のための繊維芽細胞成長パターン
CN104744591B (zh) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 β淀粉样蛋白结合蛋白
WO2012024187A1 (en) 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins
WO2012045882A2 (en) 2010-10-07 2012-04-12 Ac Immune S.A. Pharmaceutical composition
WO2012051498A2 (en) 2010-10-15 2012-04-19 The Board Of Regents Of The University Of Texas System Antibodies that bind amyloid oligomers
CA2827027C (en) 2011-02-11 2019-06-04 Wista Laboratories Ltd. Phenothiazine diaminium salts and their use
US9527894B2 (en) 2011-04-28 2016-12-27 Universitaet Leipzig Polymutant tau protein variants and their use for recapitulating human tauopathies
JP6457263B2 (ja) 2011-05-20 2019-01-23 オリゴメリックス インコーポレイテッド タウプロテアーゼ組成物および使用方法
UA115657C2 (uk) 2011-09-19 2017-12-11 Аксон Ньюросайєнс Сє Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла
MX354662B (es) * 2011-10-07 2018-03-14 Ac Immune Sa Anticuerpos fosfoespecificos que reconocen la tau.
JP6563193B2 (ja) 2011-11-13 2019-08-21 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート Ｄｃｐｌａのエステル、およびそれを用いた処置の方法
MX359555B (es) 2012-07-03 2018-10-02 Univ Washington Anticuerpos para tau.
WO2014141124A1 (en) * 2013-03-13 2014-09-18 Institut National De La Sante Et De La Recherche Medicale Erk-pathway activating compound for preventing or treating leptin resistance
EP2970452A2 (de) 2013-03-15 2016-01-20 AC Immune S.A. Anti-tau-antikörper und verfahren zur verwendung
US9675796B2 (en) 2013-11-10 2017-06-13 Brainsgate Ltd. Implant and delivery system for neural stimulator
MX2016007208A (es) 2013-12-20 2016-07-21 Hoffmann La Roche Anticuerpos anti-tau(ps422) humanizados y metodos de uso.
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
JP6913018B2 (ja) 2014-07-08 2021-08-04 ニューヨーク・ユニバーシティ タウイメージングリガンド、ならびにタウ異常症の診断および治療におけるそれらの使用
WO2016112078A2 (en) * 2015-01-08 2016-07-14 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
EP3093043B1 (de) 2015-05-13 2018-11-14 Brainsgate Ltd. Implantat und abgabesystem für nervenstimulator
CN113929779B (zh) 2015-06-24 2025-02-25 豪夫迈·罗氏有限公司 人源化的抗-Tau(pS422)抗体和使用方法
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
WO2017027685A2 (en) 2015-08-13 2017-02-16 New York University Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy
AU2016361503B2 (en) 2015-11-24 2021-08-26 Massachusetts Institute Of Technology Systems and methods for preventing, mitigating, and/or treating dementia
JOP20200228A1 (ar) 2015-12-21 2017-06-16 Novartis Ag تركيبات وطرق لخفض تعبير البروتين tau
MY197836A (en) 2016-07-12 2023-07-20 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
KR102869711B1 (ko) 2016-11-17 2025-10-15 코그니토 쎄라퓨틱스, 인코포레이티드 시각 자극을 통한 신경 자극 방법 및 시스템
CN110267985B (zh) 2017-01-04 2023-05-23 H.隆德贝克有限公司 用于治疗眼科疾病的特异性针对过度磷酸化τ蛋白的抗体
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
CN111655319A (zh) * 2017-10-10 2020-09-11 麻省理工学院 用视觉刺激同步脑中γ振荡治疗痴呆
CN111565698A (zh) 2017-10-10 2020-08-21 麻省理工学院 用于预防、减轻和/或治疗痴呆的系统和方法
US10960225B2 (en) 2017-10-10 2021-03-30 Massachusetts Institute Of Technology Systems and methods for preventing, mitigating, and/or treating dementia via visual stimulation that binds higher order brain regions, reduces neurodegeneration and neuroinflammation, and improves cognitive function
US20220273779A1 (en) * 2018-11-19 2022-09-01 The Board Of Regents Of The University Of Texas System Tau peptide antigens and antibodies binding thereto for the treatment of tauopathies
EP3918323A4 (de) 2019-01-30 2022-12-28 TrueBinding, Inc. Anti-gal3-antikörper und verwendungen davon
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874694A (en) * 1987-04-07 1989-10-17 The Rockefeller University Use of phosphoprotein patterns for diagnosis of neurological and psychiatric disorders
DE3726721A1 (de) * 1987-08-11 1989-02-23 Koehler Chemie Dr Franz Verwendung eines calcium-chelats der ethanolaminophosphorsaeure zur prophylaxe oder therapie
GB8724412D0 (en) * 1987-10-19 1987-11-25 Medical Res Council Protein
JPH0725786A (ja) * 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
IE911869A1 (en) * 1990-06-01 1991-12-04 Regeneron Pharma A family of map2 protein kinases
DE4028970A1 (de) 1990-09-12 1992-03-19 Kettner Verpackungsmaschf Transportrolle
AU675410B2 (en) 1991-08-09 1997-02-06 Massachusetts Institute Of Technology TAU/neurofilament protein kinases PK40 and PK36
DE69535901D1 (de) * 1994-10-28 2009-01-29 Max Planck Gesellschaft Proteinkinase npk-110

Also Published As

Publication number Publication date
JP2000037188A (ja) 2000-02-08
JP2000026498A (ja) 2000-01-25
EP0911398B1 (de) 2008-06-11
EP0909814A3 (de) 2003-02-26
ES2302343T3 (es) 2008-07-01
JPH07507044A (ja) 1995-08-03
ATE398176T1 (de) 2008-07-15
WO1993011231A1 (en) 1993-06-10
AU681071B2 (en) 1997-08-21
EP0911398A2 (de) 1999-04-28
EP0909814B1 (de) 2008-02-13
EP0911390A3 (de) 2003-02-26
DE69233723T2 (de) 2009-02-05
DE69230148T2 (de) 2000-05-04
DE69233723D1 (de) 2008-03-27
ES2136654T3 (es) 1999-12-01
AU2865697A (en) 1997-12-04
US6200768B1 (en) 2001-03-13
AU707736B2 (en) 1999-07-15
EP0618968A1 (de) 1994-10-12
EP0911398A3 (de) 2003-02-26
EP0909814A2 (de) 1999-04-21
ATE438716T1 (de) 2009-08-15
ATE185599T1 (de) 1999-10-15
EP2009104A1 (de) 2008-12-31
EP0911390B1 (de) 2009-08-05
DE69230148D1 (de) 1999-11-18
US20090162336A1 (en) 2009-06-25
DK0618968T3 (da) 2000-04-10
EP0618968B1 (de) 1999-10-13
DE69233767D1 (de) 2009-09-17
JP2000032983A (ja) 2000-02-02
AU3256093A (en) 1993-06-28
CA2125298A1 (en) 1993-06-10
DE69233736D1 (de) 2008-07-24
EP0911390A2 (de) 1999-04-28

Similar Documents

Publication Publication Date Title
DE69233723D1 (de) Verwendung von Proteinkinasen zur Diagnose und Behandlung der Alzheimer Krankheit
DE69635740D1 (de) Diagnose und behandlung von mit aur-1 und/oder aur-2 assoziierten erkrankungen
DE69334246D1 (de) Verbesserte reagentien und methoden zur diagnose und behandlung von diabetes und stiff man syndrome
ATE210296T1 (de) Immunologisches nachweisverfahren von antikörpern,die gegen gewebe-transglutaminase (ttg) gerichtet sind, verwendung von ttg zur diagnose und therapiekontrolle sowie orales pharmazeutisches mittel enthaltend ttg
DE69129302D1 (de) Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen
ES2094733T3 (es) Deteccion de enfermedades o disfunciones neurologicas.
DK47588D0 (da) Forloeberprotein for apc-polypeptid, dna koderende for dette samt anvendelse af dna og af proteinet til diagnose
ATE182180T1 (de) Lamanin-ketten: diagnostische und therapeutische verwendung
DE3786200D1 (de) Diagnostische verfahren zum nachweis von lymphomen bei menschen.
DE3854767D1 (de) Diagnostika und Impfstoffe für Mycobacteria in der Volksgesundheit, in der medizinischen und veterinären Praxis
ATE244299T1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
WO1995005604A3 (en) Methods for the diagnosis of alzheimer's disease
DE60122673D1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
DE69505376D1 (de) Alpha b crystallin zur verwendung in diagnose und therapie von autoimmunkrankheiten, besonders multipler skerose
ATE462717T1 (de) Verfahren und zusammensetzungen für die diagnose und die behandlung von krankheiten, die mit eisenüberschuss oder eisenmangel assoziiert sind
DE60235996D1 (de) Diagnostische und therapeutische verwendung von f-box-proteinen bei morbus alzheimer und verwandten neurodegenerativen erkrankungen
DE69734890D1 (de) Rdgb-proteine
ATE240352T1 (de) Komplexverbindungen zur diagnose von gefässerkrankungen
ATE335502T1 (de) Verwendung von glukose-6-phosphate-isomerase und dagegen gerichteten antikörpern zur diagnose und therapeutischen behandlung von arthritis, und test von zur behandlung der arthritis wirksamen verbindungen
ATE334145T1 (de) Neues menschliches ulip/crmp protein und seine verwendung zur diagnose zur behandlung von krebs und von neurologischen paraneoplastischen syndromen
ATE365175T1 (de) Diagnostische und therapeutische verwendung von humanen maguinproteinen und nukleinsäuren bei neurodegenerativen krankheiten
ATE441859T1 (de) Verfahren zur diagnose der immunität wiederkehrenden spontanen schwangerschaftsabbruchs sowie verfahren zur behandlung und überwachung
RU95121437A (ru) Способ диагностики доминирующего повреждения при сочетанных травмах опорно-двигательного аппарата и головного мозга
FI974209L (fi) Menetelmät valmistaa muuntuneita CD44-pintaproteiineja ja näitä proteiineja vastaan vaikuttavia vasta-aineita
ATE103179T1 (de) Behandlung und diagnose von klauenseuche unter verwendung der basischen protease von bacteroides nodosus.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties